The newer and emerging treatments for atopic dermatitis (AD) focus on blockade 
of inflammatory cytokines, especially those that derive from T helper cell type 
2 (TH2) and are associated with a pathway of immunoglobulin E (IgE) 
sensitization. Among the proinflammatory cytokines that have been identified as 
promising therapeutic targets are chemoattractant receptor-homologous molecule 
expressed on TH2 cells (CRTH2), IgE, thymic stromal lymphopoietin (TSLP), and 
several monoclonal antibodies that block key cytokine pathways in the innate 
immune response. Two agents that have been studied in phase III clinical trials 
are the boronbased phosphodiesterase-4 (PDE-4) inhibitor, crisaborole, and 
dupilumab, an antibody that inhibits the interleukin-4/ IL-13 receptor α chain. 
Semin Cutan Med Surg 35(supp5):S92-S96.